Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases

Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases

Shots:

  • BI and Healx team up to discover new indications targeting rare neurological diseases by harnessing Healx’s AI-based drug discovery platform, Healnet to advance BI’s pipeline
  • The collaboration combines BI’s expertise for drug development, especially in rare neurological conditions with Healx’s AI-powered drug discovery platform. Healx will utilize its data analysis and technological capabilities to help BI in prioritizing selected indications for further research
  • Additionally, Healx has its experience in fragile X syndrome as well as Pitt-Hopkins syndrome and has identified 8 drug candidates for fragile X syndrome leveraging Healnet, out of which 1 is progressing towards P-IIa study

Click here to­ read full press release/ article | Ref: Healx | Image: Crunchbase